{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:51:33Z","timestamp":1781635893414,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic cancer is a common malignant tumor. We focused on exploring the function of miR-641 in stem cell characteristics for pancreatic cancer cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      MiR-641 expression was analyzed based on The Cancer Genome Atlas (TCGA) pancreatic cancer database and clinical samples. The miR-641 knockdown within pancreatic cancer was performed by cell transfection. CCK8, transwell, and flow cytometry were performed for analyzing cell growth, invasion as well as stem-cell-like features separately. Meanwhile, this study carried out the dual luciferase reporter gene assay.\n                      <jats:italic>In viv<\/jats:italic>\n                      o xenograft tumor assay was also performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MiR-641 expression increased in clinical pancreatic cancer tissues and cells compared with normal cells. MiR-641 predicted poor survival rate of pancreatic cancer patients. MiR-641 down-regulation inhibited pancreatic cancer cell proliferation, clone forming ability, invasion and migration. Down-regulation of miR-641 inhibited the capability of sphere-forming, reduced CD133\u2009+\u2009and CD44\u2009+\u2009cell quantities, and suppressed CD133, CD44, and Oct4 expression in Down-regulation of miR-641 cells. MiR-641 targeted TMEFF2\/MEK\/PI3K for promoting pancreatic cancer cells\u2019 stem-cell-like characteristics. MiR-641 also promoted tumor growth in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MiR-641 acts as an oncogene that promotes pancreatic cancer cell growth, invasion as well as stem-cell-like features, which is realized by regulating the expression of TMEFF2.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12672-026-04584-2","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:46:08Z","timestamp":1770475568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MiR-641 targets TMEFF2\/MEK\/PI3K to promote stem cell characteristics of pancreatic cancer cells"],"prefix":"10.1007","volume":"17","author":[{"given":"Hongchao","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"issue":"9","key":"4584_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326(9):851\u201362.","journal-title":"JAMA"},{"issue":"10485","key":"4584_CR2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop TF, Javed AA, Oba A, et al. Pancreatic cancer. Lancet (London England). 2025;405(10485):1182\u2013202.","journal-title":"Lancet (London England)"},{"key":"4584_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/bs.pmbts.2019.03.006","volume":"164","author":"Y Sunami","year":"2019","unstructured":"Sunami Y, Kleeff JR. Immunotherapy of pancreatic cancer. Prog Mol Biol Transl Sci. 2019;164:189\u2013216.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"1","key":"4584_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1055-3207(25)00080-8","volume":"35","author":"K Washington","year":"2026","unstructured":"Washington K. Pancreatic cancer. Surg Oncol Clin N Am. 2026;35(1):xv\u2013xvi.","journal-title":"Surg Oncol Clin N Am"},{"issue":"2","key":"4584_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ejso.2023.01.001","volume":"49","author":"S Reide","year":"2023","unstructured":"Reide S, Rangelova K, Dopazo E. Pancreatic cancer. Eur J Surg Oncol: J Eur Soc Surg Oncol Br Association Surg Oncol. 2023;49(2):521\u20135.","journal-title":"Eur J Surg Oncol: J Eur Soc Surg Oncol Br Association Surg Oncol"},{"issue":"3","key":"4584_CR6","first-page":"211","volume":"39","author":"F Chen","year":"2024","unstructured":"Chen F, Zheng Y, Zhou H, et al. The regulatory role of SNORD35A in pancreatic cancer involves the HGF\/C-Met pathway. Cancer Biother Radiopharm. 2024;39(3):211\u201322.","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"4584_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3390\/biom10050769","volume":"10","author":"C Georgikou","year":"2020","unstructured":"Georgikou C, Buglioni L, Bremerich M, et al. Novel broccoli Sulforaphane-Based analogues inhibit the progression of pancreatic cancer without side effects. Biomolecules. 2020;10(5):769.","journal-title":"Biomolecules"},{"issue":"9","key":"4584_CR8","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.62347\/AVYM3477","volume":"14","author":"Y Tang","year":"2024","unstructured":"Tang Y, Guo S, Yu N, et al. ZIP4: a promising early diagnostic and therapeutic targets for pancreatic cancer. Am J Cancer Res. 2024;14(9):4652\u201364.","journal-title":"Am J Cancer Res"},{"issue":"8","key":"4584_CR9","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1158\/2159-8290.CD-24-1712","volume":"15","author":"W Xie","year":"2025","unstructured":"Xie W, Yu X, Yang Q, et al. The immunomechanical checkpoint PYK2 governs monocyte-to-macrophage differentiation in pancreatic cancer. Cancer Discov. 2025;15(8):1740\u201365.","journal-title":"Cancer Discov"},{"key":"4584_CR10","doi-asserted-by":"publisher","first-page":"217350","DOI":"10.1016\/j.canlet.2024.217350","volume":"610","author":"B Yu","year":"2025","unstructured":"Yu B, Shao S, Ma W. Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy. Cancer Lett. 2025;610:217350.","journal-title":"Cancer Lett"},{"issue":"12","key":"4584_CR11","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.3724\/abbs.2022194","volume":"54","author":"H Huang","year":"2022","unstructured":"Huang H, Li X, Zhang X, et al. DSCR9\/miR-21-5p axis inhibits pancreatic cancer proliferation and resistance to gemcitabine via BTG2 signaling. Acta Biochim Biophys Sin. 2022;54(12):1775\u201388.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"7","key":"4584_CR12","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/cbf.3836","volume":"41","author":"Z Li","year":"2023","unstructured":"Li Z, Duan Y, Yan S, et al. The miR-302\/367 cluster: aging, inflammation, and cancer. Cell Biochem Funct. 2023;41(7):752\u201366.","journal-title":"Cell Biochem Funct"},{"issue":"2","key":"4584_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/cancers14020264","volume":"14","author":"J Tse","year":"2022","unstructured":"Tse J, Pierce T, Carli ALE, et al. Onco-miR-21 promotes Stat3-dependent gastric cancer progression. Cancers. 2022;14(2):264.","journal-title":"Cancers"},{"issue":"1","key":"4584_CR14","doi-asserted-by":"publisher","first-page":"11243","DOI":"10.1038\/s41598-024-61660-9","volume":"14","author":"H Zhu","year":"2024","unstructured":"Zhu H, Ruan X, Zhao K, et al. The miR-641-STIM1 and SATB1 axes play important roles in the regulation of the Th17\/Treg balance in ITP. Sci Rep. 2024;14(1):11243.","journal-title":"Sci Rep"},{"key":"4584_CR15","first-page":"5203839","volume":"2022","author":"L Li","year":"2022","unstructured":"Li L, Wei D, Zhang J, et al. MiR-641 inhibited cell proliferation and induced apoptosis by targeting NUCKS1\/PI3K\/AKT signaling pathway in breast cancer. Comput Math Methods Med. 2022;2022:5203839.","journal-title":"Comput Math Methods Med"},{"key":"4584_CR16","doi-asserted-by":"publisher","first-page":"110346","DOI":"10.1016\/j.biopha.2020.110346","volume":"129","author":"K Li","year":"2020","unstructured":"Li K, Han H, Gu W, et al. Long non-coding RNA LINC01963 inhibits progression of pancreatic carcinoma by targeting miR-641\/TMEFF2. Biomed Pharmacother. 2020;129:110346.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"4584_CR17","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cbin.11152","volume":"43","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Liu B, Zhang P, et al. LncRNA TUSC8 inhibits the invasion and migration of cervical cancer cells via miR-641\/PTEN axis. Cell Biol Int. 2019;43(7):781\u20138.","journal-title":"Cell Biol Int"},{"issue":"3","key":"4584_CR18","first-page":"e332","volume":"3","author":"S Setua","year":"2017","unstructured":"Setua S, Khan S, Doxtater K, et al. miR-145: revival of a dragon in pancreatic cancer. J Nat Sci. 2017;3(3):e332.","journal-title":"J Nat Sci"},{"issue":"2","key":"4584_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00018-019-03278-z","volume":"77","author":"J Yang","year":"2020","unstructured":"Yang J, Ren B, Yang G, et al. The enhancement of glycolysis regulates pancreatic cancer metastasis. Cellular and molecular life sciences\u202f: CMLS. 2020;77(2):305\u201321.","journal-title":"Cellular and molecular life sciences : CMLS"},{"issue":"3","key":"4584_CR20","doi-asserted-by":"publisher","first-page":"101461","DOI":"10.1016\/j.xcrm.2024.101461","volume":"5","author":"B Ku","year":"2024","unstructured":"Ku B, Eisenbarth D, Baek S, et al. PRMT1 promotes pancreatic cancer development and resistance to chemotherapy. Cell Rep Med. 2024;5(3):101461.","journal-title":"Cell Rep Med"},{"issue":"1","key":"4584_CR21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11605-016-3222-z","volume":"21","author":"S Setua","year":"2017","unstructured":"Setua S, Khan S, Yallapu MM, et al. Restitution of tumor suppressor MicroRNA-145 using magnetic nanoformulation for pancreatic cancer therapy. J Gastrointest Surg. 2017;21(1):94\u2013105.","journal-title":"J Gastrointest Surg"},{"issue":"9","key":"4584_CR22","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.7150\/jca.34902","volume":"11","author":"S Chen","year":"2020","unstructured":"Chen S, Xu J, Su Y, et al. MicroRNA-145 suppresses epithelial to mesenchymal transition in pancreatic cancer cells by inhibiting TGF-\u03b2 signaling pathway. J Cancer. 2020;11(9):2716\u201323.","journal-title":"J Cancer"},{"issue":"13","key":"4584_CR23","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.7150\/jca.86974","volume":"14","author":"R Avsar","year":"2023","unstructured":"Avsar R, Gurer T, Aytekin A. Bioinformatics and expression analyses of miR-639, miR-641, miR-1915-3p and miR-3613-3p in colorectal cancer pathogenesis. J Cancer. 2023;14(13):2399\u2013409.","journal-title":"J Cancer"},{"key":"4584_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12935-020-01318-4","volume":"20","author":"H Wu","year":"2020","unstructured":"Wu H, Li W, Zhu S, et al. Circular RNA circUBAP2 regulates proliferation and invasion of osteosarcoma cells through miR-641\/YAP1 axis. Cancer Cell Int. 2020;20:223.","journal-title":"Cancer Cell Int"},{"key":"4584_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12935-020-01390-w","volume":"20","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zheng R, Chen J, et al. CircRNA CDR1as\/miR-641\/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC). Cancer Cell Int. 2020;20:289.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"4584_CR26","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/cam4.1326","volume":"7","author":"J Chen","year":"2018","unstructured":"Chen J, Cui J, Guo X, et al. Increased expression of miR-641 contributes to erlotinib resistance in non-small-cell lung cancer cells by targeting NF1. Cancer Med. 2018;7(4):1394\u2013403.","journal-title":"Cancer Med"},{"issue":"12","key":"4584_CR27","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.3390\/cancers12123862","volume":"12","author":"M Masood","year":"2020","unstructured":"Masood M, Grimm S, El-Bahrawy M, et al. TMEFF2: a transmembrane proteoglycan with multifaceted actions in cancer and disease. Cancers. 2020;12(12):3862.","journal-title":"Cancers"},{"issue":"14","key":"4584_CR28","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/pros.22706","volume":"73","author":"T Green","year":"2013","unstructured":"Green T, Chen X, Ryan S, et al. TMEFF2 and SARDH cooperate to modulate one-carbon metabolism and invasion of prostate cancer cells. Prostate. 2013;73(14):1561\u201375.","journal-title":"Prostate"},{"issue":"3","key":"4584_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/cbin.10832","volume":"42","author":"B Gawe","year":"2018","unstructured":"Gawe B, Ben K, Ali N, Ellis V, et al. TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane Serine proteases implicated in prostate cancer. Cell Biol Int. 2018;42(3):273\u201380.","journal-title":"Cell Biol Int"},{"key":"4584_CR30","doi-asserted-by":"publisher","first-page":"104670","DOI":"10.1016\/j.yexmp.2021.104670","volume":"122","author":"MA Alabiad","year":"2021","unstructured":"Alabiad MA, Harb OA, Hefzi N, et al. Prognostic and clinicopathological significance of TMEFF2, SMOC-2, and SOX17 expression in endometrial carcinoma. Exp Mol Pathol. 2021;122:104670.","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"4584_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1349-7006.2011.02129.x","volume":"103","author":"H Chen","year":"2012","unstructured":"Chen H, Zhu B, Zhang C, et al. High CpG Island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer. Cancer Sci. 2012;103(1):73\u20139.","journal-title":"Cancer Sci"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04584-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04584-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04584-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:53:13Z","timestamp":1781632393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04584-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4584"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04584-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of Affiliated Hospital 6 of Nantong University approved this work, and it was conducted following the Declaration of Helsinki (No. YCN-0020\u201314\u00a0J).\u00a0The study protocol received approval from the Animal Ethics Committee of Affiliated Hospital 6 of Nantong University (YCNA-0134-JK1). In accordance with the ethical review standards of our Institutional Review Board (IRB) and \u200cRECIST 1.1 criteria\u200c, the following limits apply to this study: Single Lesion\u200c has a maximum diameter \u2264 \u200c20 mm\u200c (measured bidimensionally by caliper or imaging), Multi-Lesion Assessment\u200c must not exceed \u200c10% of the animal\u2019s total body weight\u200c, and Animals will be euthanized if tumor diameter reaches 18\u00a0mm or if signs of distress (e.g., weight loss\u2009>\u200920%, ulceration, or mobility impairment) are observed, with the tumor burden of the experimental animals involved in this study confirmed to not exceed the maximum tumor burden allowed by the guidelines. Additionally, euthanasia was performed via 5% isoflurane overdose followed by cervical dislocation, in accordance with standard protocols where anesthesia was administered using isoflurane inhalation prior to invasive procedures, and euthanasia could also involve cervical dislocation or CO\n                      2\n                      asphyxiation to meet AVMA guidelines for humane endpoints.\u00a0Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data and photographs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The protocol was approved by ethics committee of Affiliated Hospital 6 of Nantong University in accordance with the Declaration of Helsinki (No. YCN-0020\u201314\u00a0J).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial statement"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"408"}}